JP7141108B2 - 医薬製剤 - Google Patents

医薬製剤 Download PDF

Info

Publication number
JP7141108B2
JP7141108B2 JP2018561686A JP2018561686A JP7141108B2 JP 7141108 B2 JP7141108 B2 JP 7141108B2 JP 2018561686 A JP2018561686 A JP 2018561686A JP 2018561686 A JP2018561686 A JP 2018561686A JP 7141108 B2 JP7141108 B2 JP 7141108B2
Authority
JP
Japan
Prior art keywords
formula
compound
pharmaceutical composition
cyclodextrin
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018561686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516765A (ja
JP2019516765A5 (https=
Inventor
ロー、デレク
エドワード モリス シブリー、グラハム
Original Assignee
エフツージー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフツージー リミテッド filed Critical エフツージー リミテッド
Publication of JP2019516765A publication Critical patent/JP2019516765A/ja
Publication of JP2019516765A5 publication Critical patent/JP2019516765A5/ja
Application granted granted Critical
Publication of JP7141108B2 publication Critical patent/JP7141108B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018561686A 2016-05-25 2017-05-25 医薬製剤 Active JP7141108B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1609222.3A GB201609222D0 (en) 2016-05-25 2016-05-25 Pharmaceutical formulation
GB1609222.3 2016-05-25
PCT/GB2017/051494 WO2017203270A1 (en) 2016-05-25 2017-05-25 Pharmaceutical formulation

Publications (3)

Publication Number Publication Date
JP2019516765A JP2019516765A (ja) 2019-06-20
JP2019516765A5 JP2019516765A5 (https=) 2020-07-02
JP7141108B2 true JP7141108B2 (ja) 2022-09-22

Family

ID=56369959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018561686A Active JP7141108B2 (ja) 2016-05-25 2017-05-25 医薬製剤

Country Status (25)

Country Link
US (2) US10973821B2 (https=)
EP (1) EP3463365B1 (https=)
JP (1) JP7141108B2 (https=)
KR (1) KR102464150B1 (https=)
CN (1) CN109982704B (https=)
AU (1) AU2017270942B2 (https=)
CA (1) CA3024771A1 (https=)
CY (1) CY1124733T1 (https=)
DK (1) DK3463365T3 (https=)
ES (1) ES2888951T3 (https=)
GB (1) GB201609222D0 (https=)
HR (1) HRP20211795T1 (https=)
HU (1) HUE056129T2 (https=)
IL (1) IL263167B (https=)
LT (1) LT3463365T (https=)
MA (1) MA45126A (https=)
MX (1) MX382199B (https=)
MY (1) MY197663A (https=)
PL (1) PL3463365T3 (https=)
PT (1) PT3463365T (https=)
RU (1) RU2760681C2 (https=)
SG (1) SG11201810323RA (https=)
SI (1) SI3463365T1 (https=)
WO (1) WO2017203270A1 (https=)
ZA (1) ZA201807851B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609222D0 (en) * 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
WO2021222045A1 (en) * 2020-04-26 2021-11-04 Apollomics Inc. Novel pharmaceutical formulation for c-met inhibitor
CN113429396A (zh) * 2021-06-08 2021-09-24 深圳市祥根生物医药有限公司 一种五元杂芳环衍生物及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518818A (ja) 2008-04-24 2011-06-30 エフツージー リミテッド ピロール抗真菌剤
JP2017536371A (ja) 2014-11-21 2017-12-07 エフツージー リミテッド 抗真菌剤

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1051723A (https=) 1962-04-27
US3202654A (en) 1962-04-27 1965-08-24 Bristol Myers Co 6-[alpha-hydroxy-and alpha-amino-alpha-pyrrolylacetamido] penicillanic acids and salts thereof
US3252970A (en) 1963-02-27 1966-05-24 Ciba Geigy Corp Aromatization
BE631632A (https=) 1963-04-26
US3268558A (en) 1964-11-05 1966-08-23 Ortho Pharma Corp 1-r-2, 4-dinitropyrroles
US3458515A (en) 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
GB1208014A (en) 1967-03-23 1970-10-07 Glaxo Lab Ltd Cephalosporins
US3573294A (en) 1968-03-14 1971-03-30 Glaxo Lab Ltd 7 - (arylglyoxamido)cephalosporanic acids and their salts and alpha-carbonyl derivatives
BE790747A (fr) 1971-10-30 1973-02-15 Whitefin Holding Sa Stereo-isomeres du 1-(1'-(0-chloro-benzyl)-pyrrol-2'-yl) -2-dibutyl sec.-amino-ethanol et procede pour leur preparation
GB1476503A (en) 1973-06-21 1977-06-16 Sterling Drug Inc 1-arylamino-and 1-arylimino-pyrroles and preparation thereof
BE848465A (fr) 1976-11-18 1977-03-16 Stereo-isomeres de 1-(1'-benzyl-2' pyrryl)-2-disec.butylaminoethanols a activite analgesique et preparations pharmaceutiques qui les contiennent
US4316900A (en) 1977-10-05 1982-02-23 Ciba-Geigy Corporation Piperazinopyrrolobenzodiazepines
JPS57142966A (en) 1981-02-27 1982-09-03 Sagami Chem Res Center (1-alkyl-2-pyrrolyl)glyoxylic acid amide derivative
JPS57144255A (en) 1981-03-03 1982-09-06 Sagami Chem Res Center Alpha-methylthio(1-alkyl-2-pyrrolyl)acetamide derivative
US4761424A (en) 1985-10-01 1988-08-02 Warner-Lambert Company Enolamides, pharmaceutical compositions and methods for treating inflammation
FR2601368B1 (fr) 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5637592A (en) 1994-07-12 1997-06-10 Janssen Pharmaceutica N.V. Acyl derivatives of azolones
JPH10505584A (ja) 1994-07-21 1998-06-02 イーライ・リリー・アンド・カンパニー インドリジンｓＰＬＡ▲下２▼インヒビター
US5750540A (en) 1995-04-28 1998-05-12 Banyu Pharmaceutical Co., Ltd. 1,4-di-substituted piperidine derivatives
EP0747756B1 (en) 1995-06-06 2000-05-24 Agfa-Gevaert N.V. Photographic materials
JPH09249669A (ja) 1996-03-13 1997-09-22 Ono Pharmaceut Co Ltd 縮合ピロール誘導体、およびそれらを有効成分として含有する薬剤
US6133248A (en) 1997-06-13 2000-10-17 Cydex, Inc. Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
EA008723B1 (ru) 1998-06-03 2007-06-29 Джи-Пи-Ай Эн-Ай-Эл Холдингз, Инк. Аза-гетероциклические соединения, применяемые для лечения неврологических расстройств и выпадения волос
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
ATE404178T1 (de) 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
ID30409A (id) 1999-05-04 2001-11-29 Jannsen Pharmaceutica N V Eter anti jamur
WO2001008572A1 (de) 1999-07-30 2001-02-08 Norbert Heske Kanülenanordnung zum einbringen endoskopischer instrumente in einen menschlichen oder tierischen körper
CN1402629A (zh) 1999-12-23 2003-03-12 辉瑞产品公司 提供提高的药物浓度的药物组合物
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
US7202239B2 (en) 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
US6825201B2 (en) 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
JP2005501009A (ja) 2001-06-06 2005-01-13 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｃａｋインヒビターおよびその使用
RU2319699C2 (ru) 2001-06-20 2008-03-20 Дайити Санкио Компани, Лимитед Производные диаминов
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
BR0307515A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
PL372247A1 (en) 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
WO2003072028A2 (en) 2002-02-23 2003-09-04 Bristol-Myers Squibb Company Method of treating hiv infection by preventing interaction of cd4 and gp120
US20050255164A1 (en) 2002-08-15 2005-11-17 Yunging Liu Solid nano pharmaceutical formulation and preparation method thereof
US20050032871A1 (en) 2002-09-03 2005-02-10 Sugen, Inc. Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
WO2004082606A2 (en) 2003-03-13 2004-09-30 Synta Pharmaceuticals Corp. Fused pyrrole compounds
FR2854079B1 (fr) 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
RU2006117635A (ru) 2003-10-24 2007-12-10 Шеринг Акциенгезельшафт (De) Производные индолинона и их применение для лечения патологических состояний, таких как злокачественное новообразование
CA2568007A1 (en) 2004-05-28 2005-12-08 Pfizer Products Inc. Pharmaceutical compositions with enhanced performance
US20060058286A1 (en) 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
WO2006082518A1 (en) 2005-02-03 2006-08-10 Pfizer Products Inc. Pharmaceutical compositions with enhanced performance
JP5023054B2 (ja) 2005-03-31 2012-09-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としての二環式ピラゾール化合物
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
JP5172661B2 (ja) 2005-05-18 2013-03-27 エフ２ジー リミテッド 抗真菌剤
WO2007009083A2 (en) 2005-07-12 2007-01-18 Acadia Pharmaceuticals Inc. Compounds with activity at retinoic acid receptors
WO2007015866A2 (en) 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2007109605A2 (en) 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US8343548B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US20080118500A1 (en) 2006-11-16 2008-05-22 Taiwan Liposome Company Sustained releasing composition via local injection for treating eye diseases
GB0623209D0 (en) 2006-11-21 2007-01-03 F2G Ltd Antifungal agents
JP5508859B2 (ja) 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
CN101260086B (zh) 2007-03-06 2011-08-10 中国科学院上海药物研究所 蛋白酪氨酸磷酸酯酶1b抑制剂及其制备方法和用途
GB0710121D0 (en) 2007-05-25 2007-07-04 F2G Ltd Antifungal agents
US20100215747A1 (en) 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
GB0809773D0 (en) 2008-05-29 2008-07-09 F2G Ltd Antifungal combination therapy
US20100093872A1 (en) 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
CN102421435A (zh) 2009-04-28 2012-04-18 贝林格尔.英格海姆国际有限公司 使用PKC-θ抑制剂的免疫性疾病的离体治疗
JP5792807B2 (ja) 2010-06-14 2015-10-14 ダウ グローバル テクノロジーズ エルエルシー アセテートおよびサクシネートの置換が向上されたヒドロキシプロピルメチルセルロースアセテートサクシネート
EP2611529B1 (en) 2010-09-03 2019-01-23 Bend Research, Inc. Spray-drying method
EP2636409A1 (en) 2010-11-05 2013-09-11 Eisai R&D Management Co., Ltd. Combined pharmaceutical composition as antifungal agent
CA2778748A1 (en) 2011-06-01 2012-12-01 Nitto Denko Corporation Particulate preparation and method for producing the same
SG11201401597TA (en) 2011-11-29 2014-05-29 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
CN104427979B (zh) 2012-04-11 2018-02-16 陶氏环球技术有限责任公司 具有特定的取代基分布的酯化的纤维素醚
MX2015002430A (es) 2012-08-24 2015-06-22 Dow Global Technologies Llc Acetato-succinatos de hidroxialquilmetilcelulosa.
KR102138546B1 (ko) 2012-08-24 2020-07-28 다우 글로벌 테크놀로지스 엘엘씨 부분적으로 가교결합된 에스테르화된 셀룰로즈 에테르
WO2014114575A1 (en) 2013-01-22 2014-07-31 F. Hoffmann-La Roche Ag Pharmaceutical composition with improved bioavailability
HUE054186T2 (hu) 2013-07-19 2021-08-30 Boehringer Ingelheim Vetmedica Gmbh Éterezett ciklodextrin-származékokat tartalmazó, tartósított, folyékony, vizes gyógyászati készítmény
WO2015007759A1 (en) 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
EP3076951B1 (en) 2013-12-05 2020-09-30 Celal Albayrak Process for the production of drug formulations for oral administration
PT107568B (pt) 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
GB201609222D0 (en) * 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518818A (ja) 2008-04-24 2011-06-30 エフツージー リミテッド ピロール抗真菌剤
JP2017536371A (ja) 2014-11-21 2017-12-07 エフツージー リミテッド 抗真菌剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
F2G begins F901318 Phase I clinical study for treatment of aspergillus infections，2014年09月04日，オンライン、［２０２１年４月２日検索］URL:<http://www.news-medical.net/news/20140904/F2G-begins-F901318-Phase-I-clinical-study-for-treatment-of-aspergillus-infections.aspx>
PNAS，2016年11月08日，Vol.113,No.45，p.12809-12814

Also Published As

Publication number Publication date
RU2760681C2 (ru) 2021-11-29
CN109982704B (zh) 2023-10-24
GB201609222D0 (en) 2016-07-06
ES2888951T3 (es) 2022-01-10
MX382199B (es) 2025-03-13
US20210186967A1 (en) 2021-06-24
JP2019516765A (ja) 2019-06-20
NZ748394A (en) 2024-11-29
KR102464150B1 (ko) 2022-11-07
PT3463365T (pt) 2021-09-28
ZA201807851B (en) 2022-04-28
AU2017270942B2 (en) 2022-07-21
CN109982704A (zh) 2019-07-05
KR20190013865A (ko) 2019-02-11
US20190328737A1 (en) 2019-10-31
EP3463365A1 (en) 2019-04-10
IL263167A (en) 2018-12-31
CA3024771A1 (en) 2017-11-30
EP3463365B1 (en) 2021-08-25
SG11201810323RA (en) 2018-12-28
MY197663A (en) 2023-06-30
MA45126A (fr) 2021-04-14
LT3463365T (lt) 2021-11-10
AU2017270942A1 (en) 2018-12-06
WO2017203270A1 (en) 2017-11-30
RU2018142381A3 (https=) 2020-09-30
HRP20211795T1 (hr) 2022-03-18
BR112018074162A2 (pt) 2019-03-06
US10973821B2 (en) 2021-04-13
HUE056129T2 (hu) 2022-01-28
MX2018014232A (es) 2019-03-28
SI3463365T1 (sl) 2022-01-31
PL3463365T3 (pl) 2022-01-10
IL263167B (en) 2022-07-01
RU2018142381A (ru) 2020-06-25
CY1124733T1 (el) 2022-07-22
DK3463365T3 (da) 2021-09-20

Similar Documents

Publication Publication Date Title
US20210186967A1 (en) Pharmaceutical formulation
JP5058150B2 (ja) 安定化医薬組成物
US20200397740A1 (en) 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
IL296355A (en) Oral hsp90 inhibitor formulations and related methods
US20110002989A1 (en) Methods, dosage forms and kits for administering ziprasidone without food
JP2025134801A (ja) オラパリブの溶解度及び生体利用効率が改善された組成物
WO2012135338A1 (en) Processes for preparing tofacitinib salts
CN101175491B (zh) 磺酰胺化合物用于提高药物的药代动力学的用途
JP2017536371A (ja) 抗真菌剤
KR20200090359A (ko) Fab I 저해제를 포함하는 주사제용 조성물 및 그 제조방법
CN107530342A (zh) 口服给药用医药组合物
TWI762789B (zh) 包含他克莫司的持續釋放藥物製劑
BR112018074162B1 (pt) Método para produzir uma composição farmacêutica
JP2020015690A (ja) レボセチリジン含有錠剤
CN110678464A (zh) 马赛替尼的晶型

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190118

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220428

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220809

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220902

R150 Certificate of patent or registration of utility model

Ref document number: 7141108

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250